Clinical Trials Directory

Trials / Terminated

TerminatedNCT03691038

Comparison of Conventional Dose Regimen and New Dose Regimen of Pregabalin

Comparison of Conventional Flexible Dose Regimen of Pregabalin and New Flexible Dose Regimen of Pregabalin Using Low Dose: A Randomized Controlled Trial

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Kangbuk Samsung Hospital · Academic / Other
Sex
All
Age
19 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to propose a new flexible dose regimen starting from 75mg using the low dose pregabalin 25 mg and 50 mg comparing the side effect and compliance with the conventional flexible dose regimen staring from 150mg using the pregabalin 75mg.

Detailed description

Pregabalin has been shown to be effective as a first-line medication for neuropathic pain but it appears to have several side effects such as dizziness, drowsiness, and edema, which lowers compliance with medications. A way to reduce side effects is the flexible dose regimen, which reaches the target dose to treat the drug. The proposed flexible dose regimen is a regimen that begins with twice the prevalence of 75 mg. However, dizziness is the most common side effect up to 20% in conventional flexible dose regimen. Therefore, the aim of this study was to propose a new flexible regimen starting at a dose less than the existing dose and to compare compliance with pregabaline according to both methods

Conditions

Interventions

TypeNameDescription
DRUGPregabalin 75mg bidThrough the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
DRUGPregabalin 25mg, 50mgThrough the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg

Timeline

Start date
2018-10-10
Primary completion
2019-10-30
Completion
2019-10-30
First posted
2018-10-01
Last updated
2020-09-04

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03691038. Inclusion in this directory is not an endorsement.